The decision by NICE not to recommend the long-acting CAB-LA for NHS availability leaves many underserved populations without access to effective HIV prevention. Stakeholders argue this exacerbates existing health inequities.
HIV charities and healthcare professionals expressed profound disappointment over NICE's draft guidance, emphasizing CAB-LA as a potential game changer in HIV prevention for the underserved who struggle to access oral PrEP.
Experts warn that the UK's sexual health services are at breaking point, with two-thirds unable to access PrEP, highlighting a critical need for improved availability of long-acting options like CAB-LA.
The groups advocating for CAB-LA cite the HIV Action Plan's goal to end new transmissions by 2030, arguing that the failure to adopt this drug will impede progress on reducing infection rates.
Collection
[
|
...
]